378 related articles for article (PubMed ID: 26990023)
1. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
3. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
7. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
9. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
Gimeno-Ballester V; Mar J; O'Leary A; Adams R; San Miguel R
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):85-93. PubMed ID: 27500437
[TBL] [Abstract][Full Text] [Related]
15. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
19. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
20. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]